Tuesday, August 14, 2012
Norton Scientific: Pfizer’s Drug Against Alzheimer’s Fails 1st Study ...
Norton Scientific: Pfizer’s Drug Against Alzheimer’s Fails 1st Study ...: http://toricharlie401.blog.com/2012/08/12/pfizer%E2%80%99s-drug-against-alzheimer%E2%80%99s-fails-1st-study-reddit-livejournal-blogfc2-zimbi...
Pfizer’s Drug Against Alzheimer’s Fails 1st Study Blogfc2 - Zimbio -Blog
http://toricharlie401.blog.com/2012/08/12/pfizer%E2%80%99s-drug-against-alzheimer%E2%80%99s-fails-1st-study-reddit-livejournal-blogfc2-zimbio/
Bapineuzumab, the treatment being developed by Elan, Johnson & Johnson and Pfizer for Alzheimer’s disease has failed to show signs of effectiveness in one of the four late-stage tests in patients.
“While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer’s disease will be gained following the availability of additional data,” said Pfizer’s head of primary care medicines development.
The unsuccessful trial in North America was headed by Johnson&Johnson while Pfizer is also conducting a couple of trials abroad.
Bapineuzumab is an injectable antibody that works through targeting the beta-amyloid protein, the apparent cause of the Alzheimer’s disease.
Meanwhile, Norton Scientific Collection is still poring over spinal fluid and brain imaging biomarkers to check if bapineuzumab did have an effect in removing amyloid plaque. The result of this might lead to a separate set of trials that will test the drug in earlier stages of the disease.
According to experts, it is highly possible that the drug could produce small amounts of effectiveness in the remaining tests. Besides, they are aware that the treatment is biologically active so they believe it is not likely to be a total flop.
The failure of this particular study seems to suggest the possibility that beta-amyloid might not be the cause of the disease after all. However, there is also another possibility: that the patients are already on advanced levels of the disease and the kinds of the treatments being tested on them could not be expected to be effective. Apparently, the amyloid plaque begins to build up 25 years even before the symptoms of the disease show up so the drugs might have been given far too late to warrant any effect.
“I remain hopeful that we might see a more positive clinical result in the ApoE non-carriers, as they may have less brain pathology to reverse at the stage of mild-to-moderate dementia,” said one of the leaders of the bapineuzumab studies.
Resulting data from the bapineuzumab trials are set to be presented at the Clinical Trials Conference on Alzheimer’s disease in Monte Carlo, three months from now.
“While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer’s disease will be gained following the availability of additional data,” said Pfizer’s head of primary care medicines development.
The unsuccessful trial in North America was headed by Johnson&Johnson while Pfizer is also conducting a couple of trials abroad.
Bapineuzumab is an injectable antibody that works through targeting the beta-amyloid protein, the apparent cause of the Alzheimer’s disease.
Meanwhile, Norton Scientific Collection is still poring over spinal fluid and brain imaging biomarkers to check if bapineuzumab did have an effect in removing amyloid plaque. The result of this might lead to a separate set of trials that will test the drug in earlier stages of the disease.
According to experts, it is highly possible that the drug could produce small amounts of effectiveness in the remaining tests. Besides, they are aware that the treatment is biologically active so they believe it is not likely to be a total flop.
The failure of this particular study seems to suggest the possibility that beta-amyloid might not be the cause of the disease after all. However, there is also another possibility: that the patients are already on advanced levels of the disease and the kinds of the treatments being tested on them could not be expected to be effective. Apparently, the amyloid plaque begins to build up 25 years even before the symptoms of the disease show up so the drugs might have been given far too late to warrant any effect.
“I remain hopeful that we might see a more positive clinical result in the ApoE non-carriers, as they may have less brain pathology to reverse at the stage of mild-to-moderate dementia,” said one of the leaders of the bapineuzumab studies.
Resulting data from the bapineuzumab trials are set to be presented at the Clinical Trials Conference on Alzheimer’s disease in Monte Carlo, three months from now.
Norton Scientific: Norton Collection of Classic and Scientific Litera...
Norton Scientific: Norton Collection of Classic and Scientific Litera...: http://toricharlie.onsugar.com/Norton-Collection-Classic-Scientific-Literature---Reddit--Livejournal--Tumblr--Zimbio-24405398 As one of t...
Norton Collection of Classic and Scientific Literature Tumblr -Zimbio -Onsugar
http://toricharlie.onsugar.com/Norton-Collection-Classic-Scientific-Literature---Reddit--Livejournal--Tumblr--Zimbio-24405398
As one of the leading providers of classic literature commentaries/reviews online, Norton Collection of Classic and Scientific Literature keeps a wide array of titles from prominent to obscure authors of different genres and era.
To ensure the you will get utmost quality service from Norton Collection of Classic and Scientific Literature, we constantly update our collection to include newer titles and accomodate requested reviews of users whenever we can.
And with so many titles on our archives, it is essential for readers to be able to search something they want quickly. You’ll be delighted to know that you can zero in on your target books by giving us the author name, relevant keywords or the title itself — and wait for the results just in seconds!
For those who just want to browse around and find other interesting books on their favorite category, Norton Collection of Classic and Scientific Literature has a Bookshelf section. Every title we have comes with complete description and recommendations.
Monday, March 26, 2012
Red Cross, Better Business Bureau warn against scams in tornado-damaged areas (Tvinx :: News)
http://www.tvinx.com/red_cross_better_business_bureau_warn_against_scams_in_tornado-damaged_areas.news.20431.en
toniheading's news - LOUISVILLE, KY. (WDRB) -- The Red Cross has swarmed to tornado ravaged southern Indiana, but some people may be taking advantage of that.
Officials are warning residents about scam artists posing as Red Cross employees.
Disaster relief officials say the scammers call residents and ask them to leave their homes and pay a $25 debris removal fee.
Residents are being urged to call police if anyone claiming to represent the organization asks for money.
Meanwhile the Better Business Bureau is also issuing detailed warnings about potential scams.
view link as: http://www.wdrb.com/...n-against-scams
Norton Scientific Collection - Newsvine - norton scientific scam | Linkedin
http://nortoncollectio.livejournal.com/5106.html
toniheading - Newsvine - norton scientific scam | Tumblr
This is a review of Broad and Wade’s Betrayers of the Truth. The author uses a subtitle which is revealing: the loyalist responds to heresy not by seeing that something might be wrong, that there may be some merit to this sort of reassessment, but by defending the ideology. Zinder has managed to misread Broad and Wade in several places. There is sufficient misrepresentation to mean that he read the book very selectively. “The authors continually confound science with scientists. And the book not only fails to enlighten us on science but doesn’t even begin to provide any insight on scientific method.” (p. 94) “Thirty four cases of fraud over a 2,000 year period are documented in the book, a number roughly comparable to the number of lawyers who went to jail for Watergate. Despite this small number, the authors imply that scientific fraud is common.
toniheading - Newsvine - norton scientific scam | Tumblr
This is a review of Broad and Wade’s Betrayers of the Truth. The author uses a subtitle which is revealing: the loyalist responds to heresy not by seeing that something might be wrong, that there may be some merit to this sort of reassessment, but by defending the ideology. Zinder has managed to misread Broad and Wade in several places. There is sufficient misrepresentation to mean that he read the book very selectively. “The authors continually confound science with scientists. And the book not only fails to enlighten us on science but doesn’t even begin to provide any insight on scientific method.” (p. 94) “Thirty four cases of fraud over a 2,000 year period are documented in the book, a number roughly comparable to the number of lawyers who went to jail for Watergate. Despite this small number, the authors imply that scientific fraud is common.
Wednesday, January 4, 2012
Norton Scientific: Norton Scientific By Clinton Mccage - Wikinut | Blogspot
http://toniheading-nortonscientific.blogspot.com/2012/01/norton-scientific-by-clinton-mccage.html
Norton intends to market simple-to-use products that can be used by technicians, rather than analysts, to be incorporated into any laboratories’ own process control systems.
Norton intends to market simple-to-use products that can be used by technicians, rather than analysts, to be incorporated into any laboratories’ own process control systems.
NORTON SCIENTIFIC » MAIN | CLINTON MCCAGE
By successfully integrating guided wave laser optics, microfluidics and robust data analysis software, researchers at Norton Scientific have invented a proprietary laser-based product that is now being marketed to laboratories and universities around the world.
Targeting proteomics applications including crystallographers, the company is introducing this low-cost analytical system to researchers in biopharmaceutical and healthcare, advanced materials, food and beverage, bio-materials and in-water pollution monitoring.
Norton intends to market simple-to-use products that can be used by technicians, rather than analysts, to be incorporated into any laboratories’ own process control systems. Due to various applications of these materials, “macromolecule” covers the entire range of polymers and biopolymers − including proteins and peptides − that can be analysed using the intellectual property owned by NSI, such as contained in the revolutionary protein aggregation monitor (PAM).
Targeting proteomics applications including crystallographers, the company is introducing this low-cost analytical system to researchers in biopharmaceutical and healthcare, advanced materials, food and beverage, bio-materials and in-water pollution monitoring.
Norton intends to market simple-to-use products that can be used by technicians, rather than analysts, to be incorporated into any laboratories’ own process control systems. Due to various applications of these materials, “macromolecule” covers the entire range of polymers and biopolymers − including proteins and peptides − that can be analysed using the intellectual property owned by NSI, such as contained in the revolutionary protein aggregation monitor (PAM).
Subscribe to:
Posts (Atom)